---
title: TADalafil in early-stage Parkinson’s Disease (TAD-PD)
euct_id: 2025-521819-39-00
phase: Phase 4
status: Not yet recruiting
sponsor: Amsterdam UMC Stichting
canonical_url: "https://parkinsonspathways.com/trials/eu/2025-521819-39-00"
eu_clinical_trials_register: "https://euclinicaltrials.eu/ctis-public/view/2025-521819-39-00"
ctis_last_updated: "2026-05-08T03:32:54.124948336"
source: EU Clinical Trials Information System (CTIS)
---
# TADalafil in early-stage Parkinson’s Disease (TAD-PD)

**EU CT Number:** [2025-521819-39-00](https://euclinicaltrials.eu/ctis-public/view/2025-521819-39-00)

## Key Facts

- **Phase:** Phase 4
- **Status:** Not yet recruiting
- **Sponsor:** Amsterdam UMC Stichting
- **Start Date:** 2026-03-01
- **Completion Date:** 2026-12-01
- **Conditions:** Parkinson's disease
- **Interventions:** TADALAFIL

## Member States

Trial is authorized in 1 member state: Netherlands.

## Sites (1)

- Amsterdam UMC Research B.V., Amsterdam, Netherlands

## Eligibility (CTIS)

- **Minimum age:** 18 Years
- **Sex:** ALL

```
Condition: Parkinson's disease
Age groups: adults 18-64, elderly 65+
Sex: male, female
```

---

*Canonical: https://parkinsonspathways.com/trials/eu/2025-521819-39-00*  
*HTML version: https://parkinsonspathways.com/trials/eu/2025-521819-39-00*  
*Source data: https://euclinicaltrials.eu/ctis-public/view/2025-521819-39-00*